AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Solid Biosciences Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.

The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty’s beneficial ownership now reflects only the newly granted option, held directly.

Solid Biosciences (NASDAQ:SLDB) ha presentato un Modulo 4 di routine, comunicando che la direttrice Georgia Keresty ha ricevuto una concessione di opzioni su azioni per 77.500 azioni il 12/06/2025, con un prezzo di esercizio di 4,58 $ per azione.

L’opzione matura completamente al più presto tra il primo anniversario della concessione o immediatamente prima della prossima assemblea annuale degli azionisti, e si accelera in caso di determinati eventi di cambio di controllo. Scade il 12/06/2035. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto, e la proprietà effettiva di Keresty riflette ora solo l’opzione appena concessa, detenuta direttamente.

Solid Biosciences (NASDAQ:SLDB) presentó un Formulario 4 rutinario informando que la directora Georgia Keresty recibió una concesión de opciones sobre acciones por 77,500 acciones el 12/06/2025 con un precio de ejercicio de $4.58 por acción.

La opción se consolida completamente en la fecha que ocurra primero entre el aniversario de un año de la concesión o inmediatamente antes de la próxima junta anual de accionistas, y se acelera en ciertos eventos de cambio de control. Expira el 12/06/2035. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias, y la propiedad beneficiaria de Keresty ahora refleja únicamente la opción recién concedida, poseída directamente.

Solid Biosciences (NASDAQ:SLDB)ëŠ� 정기 Form 4ë¥� 제출하여 ì´ì‚¬ì� Georgia Kerestyê°€ 2025ë…� 6ì›� 12ì¼ì— 주당 $4.58ì� 행사가격으ë¡� 77,500ì£�ì� 스톡옵션ì� 부여받았ìŒì� 공시했습니다.

ì˜µì…˜ì€ ë¶€ì—¬ì¼ë¡œë¶€í„� 1ë…� 기ë…ì� ë˜ëŠ” ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì§ì „ ì¤� 빠른 시ì ì—� ì „ì•¡ 베스팅ë˜ë©�, 특정 ê²½ì˜ê¶� ë³€ê²� 사건 ì‹� ê°€ì†í™”ë©ë‹ˆë‹�. 만료ì¼ì€ 2035ë…� 6ì›� 12ì¼ìž…니다. 공개시장 ë‚� 보통ì£� 매매ëŠ� ë³´ê³ ë˜ì§€ 않았으며, Kerestyì� 실질 ì†Œìœ ê¶Œì€ í˜„ìž¬ 새로 ë¶€ì—¬ëœ ì˜µì…˜ë§� ì§ì ‘ 보유하고 있ìŒì� ë°˜ì˜í•©ë‹ˆë‹�.

Solid Biosciences (NASDAQ:SLDB) a déposé un Formulaire 4 de routine indiquant que la directrice Georgia Keresty a reçu une attribution d’options d’achat portant sur 77 500 actions le 12/06/2025, avec un prix d’exercice de 4,58 $ par action.

L’option acquiert sa pleine propriété à la date la plus proche entre l’anniversaire d’un an de l’attribution ou immédiatement avant la prochaine assemblée générale annuelle des actionnaires, et elle s’accélère en cas de certains événements de changement de contrôle. Elle expire le 12/06/2035. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et la propriété bénéficiaire de Keresty reflète désormais uniquement l’option nouvellement attribuée, détenue directement.

Solid Biosciences (NASDAQ:SLDB) reichte routinemäßig ein Formular 4 ein und gab bekannt, dass Direktorin Georgia Keresty am 12.06.2025 eine Aktienoptionszuteilung über 77.500 Aktien zu einem Ausübungspreis von 4,58 $ pro Aktie erhalten hat.

Die Option wird vollständig fällig, je nachdem, was zuerst eintritt: das einjährige Jubiläum der Zuteilung oder unmittelbar vor der nächsten jährlichen Hauptversammlung der Aktionäre, und beschleunigt sich bei bestimmten Kontrollwechselereignissen. Sie läuft am 12.06.2035 ab. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Kerestys wirtschaftliches Eigentum spiegelt nun nur noch die neu gewährte Option wider, die direkt gehalten wird.

Positive
  • None.
Negative
  • None.

Solid Biosciences (NASDAQ:SLDB) ha presentato un Modulo 4 di routine, comunicando che la direttrice Georgia Keresty ha ricevuto una concessione di opzioni su azioni per 77.500 azioni il 12/06/2025, con un prezzo di esercizio di 4,58 $ per azione.

L’opzione matura completamente al più presto tra il primo anniversario della concessione o immediatamente prima della prossima assemblea annuale degli azionisti, e si accelera in caso di determinati eventi di cambio di controllo. Scade il 12/06/2035. Non sono stati segnalati acquisti o vendite di azioni ordinarie sul mercato aperto, e la proprietà effettiva di Keresty riflette ora solo l’opzione appena concessa, detenuta direttamente.

Solid Biosciences (NASDAQ:SLDB) presentó un Formulario 4 rutinario informando que la directora Georgia Keresty recibió una concesión de opciones sobre acciones por 77,500 acciones el 12/06/2025 con un precio de ejercicio de $4.58 por acción.

La opción se consolida completamente en la fecha que ocurra primero entre el aniversario de un año de la concesión o inmediatamente antes de la próxima junta anual de accionistas, y se acelera en ciertos eventos de cambio de control. Expira el 12/06/2035. No se reportaron compras o ventas en el mercado abierto de acciones ordinarias, y la propiedad beneficiaria de Keresty ahora refleja únicamente la opción recién concedida, poseída directamente.

Solid Biosciences (NASDAQ:SLDB)ëŠ� 정기 Form 4ë¥� 제출하여 ì´ì‚¬ì� Georgia Kerestyê°€ 2025ë…� 6ì›� 12ì¼ì— 주당 $4.58ì� 행사가격으ë¡� 77,500ì£�ì� 스톡옵션ì� 부여받았ìŒì� 공시했습니다.

ì˜µì…˜ì€ ë¶€ì—¬ì¼ë¡œë¶€í„� 1ë…� 기ë…ì� ë˜ëŠ” ë‹¤ìŒ ì—°ë¡€ 주주ì´íšŒ ì§ì „ ì¤� 빠른 시ì ì—� ì „ì•¡ 베스팅ë˜ë©�, 특정 ê²½ì˜ê¶� ë³€ê²� 사건 ì‹� ê°€ì†í™”ë©ë‹ˆë‹�. 만료ì¼ì€ 2035ë…� 6ì›� 12ì¼ìž…니다. 공개시장 ë‚� 보통ì£� 매매ëŠ� ë³´ê³ ë˜ì§€ 않았으며, Kerestyì� 실질 ì†Œìœ ê¶Œì€ í˜„ìž¬ 새로 ë¶€ì—¬ëœ ì˜µì…˜ë§� ì§ì ‘ 보유하고 있ìŒì� ë°˜ì˜í•©ë‹ˆë‹�.

Solid Biosciences (NASDAQ:SLDB) a déposé un Formulaire 4 de routine indiquant que la directrice Georgia Keresty a reçu une attribution d’options d’achat portant sur 77 500 actions le 12/06/2025, avec un prix d’exercice de 4,58 $ par action.

L’option acquiert sa pleine propriété à la date la plus proche entre l’anniversaire d’un an de l’attribution ou immédiatement avant la prochaine assemblée générale annuelle des actionnaires, et elle s’accélère en cas de certains événements de changement de contrôle. Elle expire le 12/06/2035. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été signalé, et la propriété bénéficiaire de Keresty reflète désormais uniquement l’option nouvellement attribuée, détenue directement.

Solid Biosciences (NASDAQ:SLDB) reichte routinemäßig ein Formular 4 ein und gab bekannt, dass Direktorin Georgia Keresty am 12.06.2025 eine Aktienoptionszuteilung über 77.500 Aktien zu einem Ausübungspreis von 4,58 $ pro Aktie erhalten hat.

Die Option wird vollständig fällig, je nachdem, was zuerst eintritt: das einjährige Jubiläum der Zuteilung oder unmittelbar vor der nächsten jährlichen Hauptversammlung der Aktionäre, und beschleunigt sich bei bestimmten Kontrollwechselereignissen. Sie läuft am 12.06.2035 ab. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt gemeldet, und Kerestys wirtschaftliches Eigentum spiegelt nun nur noch die neu gewährte Option wider, die direkt gehalten wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Keresty Georgia

(Last) (First) (Middle)
C/O SOLID BIOSCIENCES INC.
500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)
CHARLESTOWN MA 02129

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Director Stock Option (Right to Buy) $4.58 06/12/2025 A 77,500 (1) 06/12/2035 Common Stock 77,500 $0.00 77,500 D
Explanation of Responses:
1. This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
/s/ by David Tyronne Howton as attorney-in-fact for Georgia Keresty 06/13/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did SLDB grant to director Georgia Keresty?

The filing reports a grant of 77,500 stock options.

What is the exercise price of the new SLDB director options?

Each option has an exercise price of $4.58 per share.

When will the options granted to Georgia Keresty vest?

They vest in full on the earlier of one year after the 06/12/2025 grant date or immediately before the next annual shareholder meeting.

Did the Form 4 show any open-market sales or purchases of SLDB stock?

No. The filing only reports the award of derivative securities; no common-stock transactions occurred.
Solid Bioscience

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Latest SEC Filings

SLDB Stock Data

471.29M
65.17M
0.52%
102.59%
13.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CHARLESTOWN